
Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML
A New Drug Application (NDA) has been submitted to the Food and Drug Administration for ziftomenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation. The submission of the …